Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal´┐Ż
138.82
+2.36 (1.73%)
After Hours: 138.82 0.00 (0.00%)
Feb 10, 4:51PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 136.76 - 144.43
52 week 130.51 - 208.88
Open 138.20
Vol / Avg. 0.00/2.03M
Mkt cap 30.67B
P/E 181.78
Div/yield     -
EPS 0.76
Shares 225.29M
Beta 0.95
Inst. own 100%
May 5, 2016
Alexion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 5:30PM EDT - Add to calendar
Apr 21, 2016
Q1 2016 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 11, 2016
Alexion Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference - 1:50PM EST - Add to calendar
Feb 3, 2016
Q4 2015 Alexion Pharmaceuticals Inc Earnings Call
Feb 3, 2016
Q4 2015 Alexion Pharmaceuticals Inc Earnings Release
Jan 12, 2016
Alexion Pharmaceuticals Inc at JPMorgan Healthcare Conference Q&A Session
Jan 12, 2016
Alexion Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 10, 2015
Alexion Pharmaceuticals Inc Investor Day
Dec 8, 2015
Alexion Pharmaceuticals Inc FDA Approval of Kanuma (sebelipase alfa) Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 9.50% 5.54%
Operating margin 13.88% 20.61%
EBITD margin - 32.60%
Return on average assets 2.03% 1.67%
Return on average equity 3.24% 2.50%
Employees 2,924 -
CDP Score - -

Address

100 College St
NEW HAVEN, CT 06510-3210
United States - Map
+1-203-2722596 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Company's product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Company's preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David L Hallal Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 48
Bio & Compensation  - Reuters
Dominique Monnet Senior Vice President, Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 50
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 45
Bio & Compensation  - Reuters